Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atenolol Pharmacogenetics in Type 2 Diabetes
NCT00925119Phase 4Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Dec 2009
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atenolol in cardiovascular disease (CVD), sponsored by University of Maryland, Baltimore. Primary endpoints: Change in Diastolic Function (Annular Tissue Velocity [Em]) at 8 weeks and Change in Free Fatty Acid Kinetics at 8 weeks. Started Dec 2009; status: terminated.
02
Drugs
atenolol
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00925119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00925119.